Skip to main content
. 2017 Mar 13;64(8):1017–1025. doi: 10.1093/cid/cix016

Figure 4.

Figure 4.

Eosinophil surface activation marker expression following single-dose administration of diethylcarbamazine (DEC) or ivermectin (IVM). Percentage of CD69+ eosinophils at day 0, day 1, and day 3 post-DEC (black circles, dashed line) and post-IVM (open circles, solid line). The gray area shows the range of normal values in >125 healthy subjects (≤2.2%). *P < .05 compared to baseline, Wilcoxon signed-rank test. Abbreviation: ND, not detectable.